Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Teclistamab, a bispecific antibody, targets CD3 and B-cell maturation antigen, showing promise in relapsed/refractory multiple myeloma.
• Daratumumab, a CD38-targeting monoclonal antibody, offers a survival benefit in multiple myeloma patients.

Purpose of the Study:

• To evaluate the efficacy and safety of teclistamab-daratumumab compared to daratumumab-based regimens in patients with multiple myeloma.
• To assess progression-free survival as the primary endpoint in a phase 3 trial.

Main Methods:

• A phase 3 randomized trial assigned patients with one to three prior therapies to teclistamab-daratumumab or daratumumab plus dexamethasone with either pomalidomide (DPd) or bortezomib (DVd).
• Progression-free survival was assessed by an independent review committee.

Main Results:

• Teclistamab-daratumumab demonstrated significantly longer progression-free survival (83.4% at 36 months) versus DPd/DVd (29.7%).
• Higher rates of complete response or better (81.8% vs. 32.1%), overall response (89.0% vs. 75.3%), and MRD negativity (58.4% vs. 17.1%) were observed with teclistamab-daratumumab.
• Serious adverse events were reported in 70.7% of the teclistamab-daratumumab group versus 62.4% in the DPd/DVd group.

Conclusions:

• Teclistamab-daratumumab significantly enhances progression-free survival in patients with multiple myeloma after one to three prior lines of therapy.
• The combination therapy represents a significant advancement in the treatment of multiple myeloma.